Treatment Outcomes of HCV Infection in People Living with HIV: A Case Series from a Single Center in Korea
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background Limited information is available on the clinical course and treatment outcomes of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection in Korea. Materials and Methods A retrospective case series was conducted of patients with HIV-HCV coinfection who received interferon (IFN)-based or direct-acting antiviral (DAA) treatment for HCV at a tertiary care hospital between 2000 and 2023. Early virological response (EVR) was defined as a 2-log reduction in HCV RNA levels or undetectable HCV RNA levels at treatment week 12. A sustained virologic response (SVR) was defined as undetectable HCV RNA at 12 weeks after treatment completion. Results Of the 33 patients with HIV-HCV coinfection, 19 received anti-HCV treatment, of whom 12 received IFN-based treatment and 10 received DAA treatment. The median age at the time of anti-HCV treatment was 49 years (interquartile range, 42–57 years) and 15 patients (79%) were male. Of the 12 patients who received IFN-based anti-HCV treatment, 10 showed EVR and 8 achieved SVR. However, 2 patients who achieved SVR experienced recurrence of HCV infection during follow-up; therefore, the overall success rate of IFN-based treatment was 50% (6/12). All 10 patients (including 3 in whom IFN-based treatment failed) who received DAA treatment (5 with previous anti-HCV treatment and 5 treatment-naïve), achieved SVR and did not experience recurrence of HCV infection during follow-up; therefore, the overall success rate of DAA treatment was 100%. Conclusion In Korean patients with HIV-HCV coinfection, treatment outcomes were better with DAA treatment than with IFN-based treatment.
Abstract
Background Limited information is available on the clinical course and treatment outcomes of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection in Korea. Materials and Methods A retrospective case series was conducted of patients with HIV-HCV coinfection who received interferon (IFN)-based or direct-acting antiviral (DAA) treatment for HCV at a tertiary care hospital between 2000 and 2023. Early virological response (EVR) was defined as a 2-log reduction in HCV RNA levels or undetectable HCV RNA levels at treatment week 12. A sustained virologic response (SVR) was defined as undetectable HCV RNA at 12 weeks after treatment completion. Results Of the 33 patients with HIV-HCV coinfection, 19 received anti-HCV treatment, of whom 12 received IFN-based treatment and 10 received DAA treatment. The median age at the time of anti-HCV treatment was 49 years (interquartile range, 42–57 years) and 15 patients (79%) were male. Of the 12 patients who received IFN-based anti-HCV treatment, 10 showed EVR and 8 achieved SVR. However, 2 patients who achieved SVR experienced recurrence of HCV infection during follow-up; therefore, the overall success rate of IFN-based treatment was 50% (6/12). All 10 patients (including 3 in whom IFN-based treatment failed) who received DAA treatment (5 with previous anti-HCV treatment and 5 treatment-naïve), achieved SVR and did not experience recurrence of HCV infection during follow-up; therefore, the overall success rate of DAA treatment was 100%. Conclusion In Korean patients with HIV-HCV coinfection, treatment outcomes were better with DAA treatment than with IFN-based treatment.
참고문헌 (39)
- Platt L, "Prevalence and burden of HCV co-infection in people living with HIV : a global systematic review and meta-analysis", Lancet Infect Dis, 16, pp.797~808 (2016)
- Lee S, "Incidence and risk factors of hepatitis C virus infection among human immunodeficiency virus(HIV)patients in a large HIV clinic in South Korea", Korean J Intern Med, 31, pp.772~778 (2016)
- Jeong SH, "Current status of hepatitis C virus infection and countermeasures in South Korea", Epidemiol Health, 39, pp.e2017017~ (2017)
- Benhamou Y, "Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group", Hepatology, 30, pp.1054~1058 (1999)
- Bräu N, "Presentation and outcome of hepatocellular carcinoma in HIV-infected patients : a U. S. -Canadian multicenter study", J Hepatol, 47, pp.527~537 (2007)
- Chen TY, "Meta-analysis : increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression", Clin Infect Dis, 49, pp.1605~1615 (2009)
- Danta M, "Impact of HIV on host-virus interactions during early hepatitis C virus infection", J Infect Dis, 197, pp.1558~1566 (2008)
- Graham CS, "Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection : a meta-analysis", Clin Infect Dis, 33, pp.562~569 (2001)
- Kirk GD, "HIV, age, and the severity of hepatitis C virus-related liver disease : a cohort study", Ann Intern Med, 158, pp.658~666 (2013)
- Thomson EC, "Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men", Gut, 60, pp.837~845 (2011)
- Lo Re V 3rd, "Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients : a cohort study", Ann Intern Med, 160, pp.369~379 (2014)
- Hawkins C, "High rates of hepatitis C virus(HCV)cure using direct-acting antivirals in HIV", HCV-coinfected patients : a real-world perspective, 2016, pp.71, 2642~2645
- Milazzo L, "Direct-acting antivirals in hepatitis C virus(HCV)-infected and HCV", HIV-coinfected patients : real-life safety and efficacy, 2017, pp.18, 284~291
- Navarro J, "Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV", HIV-coinfected patients, 2017, pp.72, 2850~2856
- Schlabe S, "Advances in the treatment of HIV", HCV coinfection in adults, 2018, pp.19, 49~64
- Lim DH, "Clinical characteristics and treatment outcomes of patients with hepatitis C virus and human immunodeficiency virus coinfection : experience at a single center in Korea", J Korean Med Sci, 36, pp.e308~ (2021)
- Ghany MG, "Diagnosis, management, and treatment of hepatitis C : an update", Hepatology, 49, pp.1335~1374 (2009)
- Wedemeyer H, "Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents", Hepatology, 56, pp.2398~2403 (2012)
- Feld JJ, "Mechanism of action of interferon and ribavirin in treatment of hepatitis C", Nature, 436, pp.967~972 (2005)
- Martinello M, "Direct-acting antiviral therapy for treatment of acute and recent hepatitis C virus infection : a narrative review", Clin Infect Dis, 77(Suppl 3), pp.S238~S244 (2023)
- Hansen N, "Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C : a Danish nationwide cohort study", BMC Infect Dis, 11, pp.177~ (2011)
- Palumbo E, "PEG-interferon in acute and chronic hepatitis C : a review", Am J Ther, 16, pp.573~578 (2009)
- Berg T, "Extended treatment duration for hepatitis C virus type 1 : comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin", Gastroenterology, 130, pp.1086~1097 (2006)
- Sánchez-Tapias JM, "Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment", Gastroenterology, 131, pp.451~460 (2006)
- Lee SS, "Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4", Antivir Ther, 13(Suppl 1), pp.9~16 (2008)
- Lafeuillade A, "Increased mitochondrial toxicity with ribavirin in HIV", HCV coinfection, 2001, pp.357, 280~281
- Lonergan JT, "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens", Clin Infect Dis, 31, pp.162~166 (2000)
- Laguno M, "Incidence and risk factors for mitochondrial toxicity in treated HIV", HCV-coinfected patients, 2005, pp.10, 423~429
- Wyles D, "Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1 : an open-label, phase 3 study", Clin Infect Dis, 65, pp.6~12 (2017)
- Sulkowski MS, "Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1 : a randomized trial", JAMA, 313, pp.1223~1231 (2015)
- Rockstroh JK, "Efficacy and safety of grazoprevir(MK-5172)and elbasvir(MK-8742)in patients with hepatitis C virus and HIV co-infection(C-EDGE CO-INFECTION) : a non-randomised, open-label trial", Lancet HIV, 2, pp.e319~e327 (2015)
- Rockstroh JK, "Efficacy and safety of glecaprevir", pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 : the EXPEDITION-2 study, 2018, pp.67, 1010~1017
- Naggie S, "Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1", N Engl J Med, 373, pp.705~713 (2015)
- Bhattacharya D, "Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus", hepatitis C virus genotype 1-coinfected patients treated in routine practice, 2017, pp.64, 1711~1720
- "HCV guidance: recommendations for testing, managing, and treating hepatitis C. Management of unique & key populations with HCV infection"[URL]
- Butt AA, "Hepatitis C treatment completion rates in routine clinical care", Liver Int, 30, pp.240~250 (2010)
- Chehl N, "HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics", Medicine(Baltimore), 98, pp.e16242~ (2019)
- "Annual report on the notified HIV/AIDS in Korea 2014"[URL]
- Beste LA, "Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication", Clin Gastroenterol Hepatol, 8, pp.972~978 (2010)